JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lippmann, W.
Right arrow Articles by Wishnick, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lippmann, W.
Right arrow Articles by Wishnick, M.
Journal of Pharmacology And Experimental Therapeutics, Vol. 150, Issue 2, 196-202, 1965
Copyright © 1965 by American Society for Pharmacology and Experimental Therapeutics


EFFECTS OF THE ADMINISTRATION OF EPSILON AMINO CAPROIC ACID ON CATECHOLAMINE AND SEROTONIN LEVELS IN THE RAT AND DOG

W. Lippmann 1 and M. Wishnick 1

1 Department of Chemical Pharmacology, Experimental Therapeutics Research, Lederle Laboratories, American Cyanamid Company, Pearl River, New York

The effects of the administration of epsilon amino caproic acid (EACA) on catecholamine and serotonin levels in the rat and dog were studied. Administration of EACA (500 mg/kg or 2000 mg/kg, orally) causes a depletion of norepinephrine in the rat heart, with several days being required for repletion; EACA at 500 mg/kg has no effect on the catecholamine or serotonin content of the brain or catecholamines in the adrenals. Of the various administered compounds structurally related to EACA none were as active as EACA in causing norepinephrine depletion from the rat heart. 5-Amino-1-pentanol and 6-amino hexanoic acid methyl ester hydrochloride show some depleting activity whereas 6-acetamido hexanoic acid, 6-dimethyl-amino hexanoic acid ethyl ester, 5-amino valeric acid hydrochloride or 6-ureido hexanoic acid show no appreciable activity. Pretreatment of the rat with the monoamine oxidase inhibitor, iproniazid, reduces the decline in norepinephrine content of the heart caused by administered EACA or reserpine. Bretylium prevents completely the depleting action observed after administered EACA or guanethidine and partially that of reserpine. Administered EACA causes a large decline in the endogenous norepinephrine content of the left atrium of the dog and no decrease in the endogenous catecholamines in the adrenals. Subendocardial hemorrhages are observed in EACA- treated dogs. The results obtained with EACA are compared with known depletors of pharmacologic interest.

Accepted on June 22, 1965







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1965 by the American Society for Pharmacology and Experimental Therapeutics.